Neurobiological basis of dyskinetic effects induced by antipsychotics: The contribution of animal models

Current Medicinal Chemistry

Volumn 20, Issue 3, 2013, Pages 389-396

  Creed, Meaghan C ^a,b   Nobrega, José N ^a,b  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Antipsychotic medications; Brain; Butyrophenones; Drug induced motor symptoms; Haloperidol; Preclinical models; Tardive dyskinesia

Indexed keywords

4 AMINOBUTYRIC ACID; BUTYROPHENONE; CLOZAPINE; DEOXYGLUCOSE; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; ENKEPHALIN; FLUPHENAZINE DECANOATE; GLUTAMIC ACID; HALOPERIDOL; MESSENGER RNA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROTRANSMITTER RECEPTOR; SEROTONIN; SYNAPTOPHYSIN;

AUTORADIOGRAPHY; CELL STRUCTURE; CORPUS STRIATUM; EXCITOTOXICITY; EXTRAPYRAMIDAL SYMPTOM; GLOBUS PALLIDUS; HABENULA; IMMEDIATE EARLY GENE; IN VIVO STUDY; LONG TERM CARE; NERVE CELL DEGENERATION; NERVE CELL PLASTICITY; NEUROIMAGING; NEUROTOXICITY; NEUROTRANSMISSION; NONHUMAN; OXIDATIVE STRESS; PRIMARY MOTOR CORTEX; PROTEIN EXPRESSION; PUTAMEN; REVIEW; SUBSTANTIA NIGRA; SUBSTANTIA NIGRA PARS RETICULATA; SUBTHALAMIC NUCLEUS; SYNAPSE; TARDIVE DYSKINESIA; TREATMENT DURATION; UPREGULATION;

EID: 84877949663     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867311320030010     Document Type: Review

References (148)

1. Wyatt, R. J., Soares & McGrath -The treatment of tardive dyskinesia: a systematic review and meta-Analysis. Schizophr Res 1999, 39 (1), 17-18. (Pubitemid 30074203)
2. Marsalek, M., Tardive drug-induced extrapyramidal syndromes. Pharmacopsychiatry 2000, 33 Suppl 1, 14-33.
3. Yassa, R.; Jeste, D. V., Gender differences in tardive dyskinesia: a critical review of the literature. Schizophr Bull 1992, 18 (4), 701-15.
4. Glazer, W. M.; Morgenstern, H.; Doucette, J. T., Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications. J Clin Psychiatry 1993, 54 (4), 133-9. (Pubitemid 23141515)
5. Casey, D. E.; Keepers, G. A., Neuroleptic side effects: acute extrapyramidal syndromes and tardive dyskinesia. Psychopharmacol Ser 1988, 5, 74-93.
6. de Boer, C.; Gaete, H. P., Neuroleptic malignant syndrome and diabetic keto acidosis. Br J Psychiatry 1992, 161, 856-8.
7. Glazer, W. M.; Morgenstern, H.; Schooler, N.; Berkman, C. S.; Moore, D. C., Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication. Br J Psychiatry 1990, 157, 585-92. (Pubitemid 20335972)
8. Howland, R. H., Drug therapies for tardive dyskinesia: Part 1. J Psychosoc Nurs Ment Health Serv 2011, 49 (6), 13-6.
9. Goetz, C. G.; Klawans, H. L.; Carvey, P., Animal models of tardive dyskinesia: their use in the search for new treatment methods. Mod Probl Pharmacopsychiatry 1983, 21, 5-20.
10. Tanner, C. M.; Klawans, H. L., Tardive dyskinesia: prevention and treatment. Clin Neuropharmacol 1986, 9 Suppl 2, S76-84. (Pubitemid 17089520)
11. Creed, M.; Hamani, C.; Nobrega, J. N., Deep brain stimulation of the subthalamic or entopeduncular nucleus attenuates vacuous chewing movements in a rodent model of tardive dyskinesia. Eur Neuropsychopharmacol 2011, 21 (5), 393-400.
12. Gunne, L. M.; Andersson, U.; Bondesson, U.; Johansson, P., Spontaneous chewing movements in rats during acute and chronic antipsychotic drug administration. Pharmacol Biochem Behav 1986, 25 (4), 897-901. (Pubitemid 17179911)
13. Turrone, P.; Remington, G.; Nobrega, J. N., The vacuous chewing movement (VCM) model of tardive dyskinesia revisited: is there a relationship to dopamine D(2) receptor occupancy? Neurosci Biobehav Rev 2002, 26 (3), 361-80. (Pubitemid 34553319)
14. Egan, M. F.; Ferguson, J.; Hyde, T. M., Effects of rating parameters on assessment of neuroleptic-induced vacuous chewing movements. Pharmacol Biochem Behav 1996, 53 (2), 401-10. (Pubitemid 26059204)
15. Marchese, G.; Casu, M. A.; Bartholini, F.; Ruiu, S.; Saba, P.; Gessa, G. L.; Pani, L., Sub-chronic treatment with classical but not atypical antipsychotics produces morphological changes in rat nigro-striatal dopaminergic neurons directly related to "early onset" vacuous chewing. Eur J Neurosci 2002, 15 (7), 1187-96. (Pubitemid 35463619)
16. Marchese, G.; Bartholini, F.; Casu, M. A.; Ruiu, S.; Casti, P.; Congeddu, E.; Tambaro, S.; Pani, L., Haloperidol versus risperidone on rat "early onset" vacuous chewing. Behav Brain Res 2004, 149 (1), 9-16. (Pubitemid 38096362)
17. Egan, M. F.; Hurd, Y.; Ferguson, J.; Bachus, S. E.; Hamid, E. H.; Hyde, T. M., Pharmacological and neurochemical differences between acute and tardive vacuous chewing movements induced by haloperidol. Psychopharmacology (Berl) 1996, 127 (4), 337-45. (Pubitemid 26356759)
18. Gunne, L. M.; Barany, S., Haloperidol-induced tardive dyskinesia in monkeys. Psychopharmacology (Berl) 1976, 50 (3), 237-40.
19. Casey, D. E., Tardive dyskinesia-Animal models. Psychopharmacol Bull 1984, 20 (3), 376-9.
20. Casey, D. E., Tardive dyskinesia: pathophysiology and animal models. J Clin Psychiatry 2000, 61 Suppl 4, 5-9. (Pubitemid 30158596)
21. Egan, M. F.; Hurd, Y.; Hyde, T. M.; Weinberger, D. R.; Wyatt, R. J.; Kleinman, J. E., Alterations in mRNA levels of D2 receptors and neuropeptides in striatonigral and striatopallidal neurons of rats with neuroleptic-induced dyskinesias. Synapse 1994, 18 (3), 178-89. (Pubitemid 24357171)
22. Sasaki, T.; Kennedy, J. L.; Nobrega, J. N., Localized changes in GABA receptor-gated chloride channel in rat brain after long-term haloperidol: relation to vacuous chewing movements. Synapse 1997, 25 (1), 73-9. (Pubitemid 27014364)
23. Abilio, V. C.; Silva, R. H.; Carvalho, R. C.; Grassl, C.; Calzavara, M. B.; Registro, S.; D'Almeida, V.; Ribeiro Rde, A.; Frussa-Filho, R., Important role of striatal catalase in aging-And reserpine-induced oral dyskinesia. Neuropharmacology 2004, 47 (2), 263-72. (Pubitemid 38824650)
24. Casey, D. E., Pathophysiology of antipsychotic drug-induced movement disorders. J Clin Psychiatry 2004, 65 Suppl 9, 25-8.
25. Seeman, P., All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2(high) receptors. CNS Neurosci Ther 2011, 17 (2), 118-32.
26. Benes, F. M.; Paskevich, P. A.; Domesick, V. B., Haloperidol-induced plasticity of axon terminals in rat substantia nigra. Science 1983, 221 (4614), 969-71. (Pubitemid 13042007)
27. Konradi, C.; Heckers, S., Antipsychotic drugs and neuroplasticity: insights into the treatment and neurobiology of schizophrenia. Biol Psychiatry 2001, 50 (10), 729-42. (Pubitemid 33086760)
28. Roberts, R. C., Effect of chronic olanzapine treatment on striatal synaptic organization. Synapse 2001, 39 (1), 8-15.
29. Jeste, D. V.; Lohr, J. B.; Manley, M., Study of neuropathologic changes in the striatum following 4, 8 and 12 months of treatment with fluphenazine in rats. Psychopharmacology (Berl) 1992, 106 (2), 154-60.
30. Chakos, M. H.; Shirakawa, O.; Lieberman, J.; Lee, H.; Bilder, R.; Tamminga, C. A., Striatal enlargement in rats chronically treated with neuroleptic. Biol Psychiatry 1998, 44 (8), 675-84. (Pubitemid 28496782)
31. Vernon, A. C.; Natesan, S.; Modo, M.; Kapur, S., Effect of chronic antipsychotic treatment on brain structure: a serial magnetic resonance imaging study with ex vivo and postmortem confirmation. Biol Psychiatry 2011, 69 (10), 936-44.
32. Harrison, P. J., The neuropathological effects of antipsychotic drugs. Schizophr Res 1999, 40 (2), 87-99. (Pubitemid 29494232)
33. Vernon, A. C.; Natesan, S.; Crum, W. R.; Cooper, J. D.; Modo, M.; Williams, S. C.; Kapur, S., Contrasting effects of haloperidol and lithium on rodent brain structure: a magnetic resonance imaging study with postmortem confirmation. Biol Psychiatry 2012, 71 (10), 855-63.
34. Kessas, M.; Creed, M.; Nobrega, J. N., An examination of synaptic proteins following chronic haloperidol in a rat model of tardive dyskinesia. Psychology & Neuroscience 2010, 3 (2), 229-237.
35. Meshul, C. K.; Stallbaumer, R. K.; Allen, C., GM1 ganglioside administration partially counteracts the morphological changes associated with haloperidol treatment within the dorsal striatum of the rat. Psychopharmacology (Berl) 1995, 121 (4), 461-9.
36. Roberts, R. C.; Gaither, L. A.; Gao, X. M.; Kashyap, S. M.; Tamminga, C. A., Ultrastructural correlates of haloperidol-induced oral dyskinesias in rat striatum. Synapse 1995, 20 (3), 234-43.
37. Meshul, C. K.; Andreassen, O. A.; Allen, C.; Jorgensen, H. A., Correlation of vacuous chewing movements with morphological changes in rats following 1-year treatment with haloperidol. Psychopharmacology (Berl) 1996, 125 (3), 238-47. (Pubitemid 26184809)
38. Klintzova, A. J.; Haselhorst, U.; Uranova, N. A.; Schenk, H.; Istomin, V. V., The effects of haloperidol on synaptic plasticity in rat's medial prefrontal cortex. J Hirnforsch 1989, 30 (1), 51-7. (Pubitemid 19078745)
39. Uranova, N. A.; Orlovskaya, D. D.; Apel, K.; Klintsova, A. J.; Haselhorst, U.; Schenk, H., Morphometric study of synaptic patterns in the rat caudate nucleus and hippocampus under haloperidol treatment. Synapse 1991, 7 (4), 253-9.
40. Roberts, R. C.; Force, M.; Kung, L., Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment. Synapse 2002, 45 (2), 78-85. (Pubitemid 34742943)
41. Roberts, R. C.; Lapidus, B., Ultrastructural correlates of haloperidol-induced oral dyskinesias in rats: a study of unlabeled and enkephalin-labeled striatal terminals. J Neural Transm 2003, 110 (9), 961-75. (Pubitemid 37100401)
42. Eastwood, S. L.; Heffernan, J.; Harrison, P. J., Chronic haloperidol treatment differentially affects the expression of synaptic and neuronal plasticityassociated genes. Mol Psychiatry 1997, 2 (4), 322-9. (Pubitemid 27450315)
43. Marin, C.; Tolosa, E., Striatal synaptophysin levels are not indicative of dopaminergic supersensitivity. Neuropharmacology 1997, 36 (8), 1115-7. (Pubitemid 27346591)
44. Nakahara, T.; Nakamura, K.; Tsutsumi, T.; Hashimoto, K.; Hondo, H.; Hisatomi, S.; Motomura, K.; Uchimura, H., Effect of chronic haloperidol treatment on synaptic protein mRNAs in the rat brain. Brain Res Mol Brain Res 1998, 61 (1-2), 238-42. (Pubitemid 28511370)
45. Klinzova, A. J.; Uranova, N. A.; Haselhorst, U.; Schenk, H., Synaptic plasticity in rat medial prefrontal cortex under chronic haloperidol treatment produced behavioral sensitization. J Hirnforsch 1990, 31 (2), 175-9. (Pubitemid 20361441)
46. Lidow, M. S.; Song, Z. M.; Castner, S. A.; Allen, P. B.; Greengard, P.; Goldman-Rakic, P. S., Antipsychotic treatment induces alterations in dendrite-And spine-Associated proteins in dopamine-rich areas of the primate cerebral cortex. Biol Psychiatry 2001, 49 (1), 1-12. (Pubitemid 32332948)
47. Eastwood, S. L.; Burnet, P. W.; Harrison, P. J., Striatal synaptophysin expression and haloperidol-induced synaptic plasticity. Neuroreport 1994, 5 (6), 677-80. (Pubitemid 24110353)
48. Benes, F. M.; Paskevich, P. A.; Davidson, J.; Domesick, V. B., Synaptic rearrangements in medial prefrontal cortex of haloperidol-treated rats. Brain Res 1985, 348 (1), 15-20. (Pubitemid 16235736)
49. Andreassen, O. A.; Jorgensen, H. A., Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats. Implications for tardive dyskinesia? Prog Neurobiol 2000, 61 (5), 525-41. (Pubitemid 30169057)
50. Andreassen, O. A.; Waage, J.; Finsen, B.; Jorgensen, H. A., Memantine attenuates the increase in striatal preproenkephalin mRNA expression and development of haloperidol-induced persistent oral dyskinesias in rats. Brain Res 2003, 994 (2), 188-92. (Pubitemid 37464882)
51. Meshul, C. K.; Casey, D. E., Regional, reversible ultrastructural changes in rat brain with chronic neuroleptic treatment. Brain Res 1989, 489 (2), 338-46. (Pubitemid 19149257)
52. Kerns, J. M.; Sierens, D. K.; Kao, L. C.; Klawans, H. L.; Carvey, P. M., Synaptic plasticity in the rat striatum following chronic haloperidol treatment. Clin Neuropharmacol 1992, 15 (6), 488-500.
53. Klintsova, A.; Uranova, N. A.; Bruk, V. P.; Khase'lkhorst, U.; Shenk, K., Effect of long-term administration of haloperidol: ultrastructural changes in the prefrontal cortex]. Zh Nevropatol Psikhiatr Im S S Korsakova 1989 89 ( 7), 110-4. (Pubitemid 19202766)
54. Petersen, R.; Finsen, B.; Andreassen, O. A.; Zimmer, J.; Jorgensen, H. A., No changes in dopamine D(1) receptor mRNA expressing neurons in the dorsal striatum of rats with oral movements induced by long-term haloperidol administration. Brain Res 2000, 859 (2), 394-7. (Pubitemid 30136118)
55. Grimm, J. W.; Chapman, M. A.; Zahm, D. S.; See, R. E., Decreased choline acetyltransferase immunoreactivity in discrete striatal subregions following chronic haloperidol in rats. Synapse 2001, 39 (1), 51-7.
56. Kelley, J. J.; Roberts, R. C., Effects of haloperidol on cholinergic striatal interneurons: relationship to oral dyskinesias. J Neural Transm 2004, 111 (8), 1075-91. (Pubitemid 39037128)
57. Meshul, C. K.; Janowsky, A.; Casey, D. E.; Stallbaumer, R. K.; Taylor, B., Coadministration of haloperidol and SCH-23390 prevents the increase in "perforated" synapses due to either drug alone. Neuropsychopharmacology 1992, 7 (4), 285-93.
58. See, R. E.; Chapman, M. A.; Meshul, C. K., Comparison of chronic intermittent haloperidol and raclopride effects on striatal dopamine release and synaptic ultrastructure in rats. Synapse 1992, 12 (2), 147-54.
59. Pakkenberg, H.; Fog, R.; Nilakantan, B., The long-term effect of perphenazine enanthate on the rat brain. Some metabolic and anatomical observations. Psychopharmacologia 1973, 29 (4), 329-36.
60. Nielsen, E. B.; Lyon, M., Evidence for cell loss in corpus striatum after longterm treatment with a neuroleptic drug (flupenithixol) in rats. Psychopharmacology (Berl) 1978, 59 (1), 85-9. (Pubitemid 9013411)
61. Fibiger, H. C.; Lloyd, K. G., Neurobiological substrates of tardive dyskinesia: theGABA hypothesis. Trends in Neurosciences 1984, 7 (12), 462-464. (Pubitemid 15156977)
62. Andreassen, O. A.; Finsen, B.; Ostergaard, K.; West, M. J.; Jorgensen, H. A., Reduced number of striatal neurons expressing preprosomatostatin mRNA in rats with oral dyskinesias after long-term haloperidol administration. Neurosci Lett 2000, 279 (1), 21-4. (Pubitemid 30026126)
63. Andreassen, O. A.; Finsen, B.; Ostergaard, K.; Sorensen, J. C.; West, M. J.; Jorgensen, H. A., The relationship between oral dyskinesias produced by long-term haloperidol treatment, the density of striatal preproenkephalin messenger RNA and enkephalin peptide, and the number of striatal neurons expressing preproenkephalin messenger RNA in rats. Neuroscience 1999, 88 (1), 27-35. (Pubitemid 28440389)
64. Andreassen, O. A.; Ferrante, R. J.; Beal, M. F.; Jorgensen, H. A., Oral Dyskinesias and striatal lesions in rats after long-term co-treatment with haloperidol and 3-nitropropionic acid. Neuroscience 1998, 87 (3), 639-48. (Pubitemid 28396550)
65. Mitchell, I. J.; Cooper, A. C.; Griffiths, M. R.; Cooper, A. J., Acute administration of haloperidol induces apoptosis of neurones in the striatum and substantia nigra in the rat. Neuroscience 2002, 109 (1), 89-99. (Pubitemid 34088149)
66. Moghaddam, B.; Bunney, B. S., Depolarization inactivation of dopamine neurons: terminal release characteristics. Synapse 1993, 14 (3), 195-200. (Pubitemid 23204945)
67. Gunne, L. M.; Andren, P. E., An animal model for coexisting tardive dyskinesia and tardive parkinsonism: a glutamate hypothesis for tardive dyskinesia. Clin Neuropharmacol 1993, 16 (1), 90-5. (Pubitemid 23028504)
68. Beal, M. F., Mechanisms of excitotoxicity in neurologic diseases. FASEB J 1992, 6 (15), 3338-44. (Pubitemid 23007098)
69. Cadet, J. L.; Kahler, L. A., Free radical mechanisms in schizophrenia and tardive dyskinesia. Neurosci Biobehav Rev 1994, 18 (4), 457-67.
70. Hansen, T. E.; Brown, W. L.; Weigel, R. M.; Casey, D. E., Risk factors for drug-induced parkinsonism in tardive dyskinesia patients. J Clin Psychiatry 1988, 49 (4), 139-41.
71. Kane, J. M.; Woerner, M.; Lieberman, J., Tardive dyskinesia: prevalence, incidence, and risk factors. J Clin Psychopharmacol 1988, 8 (4 Suppl), 52S-56S.
72. Jeste, D. V.; Caligiuri, M. P., Tardive dyskinesia. Schizophr Bull 1993, 19 (2), 303-15. (Pubitemid 23183150)
73. Tenback, D. E.; van Harten, P. N., Epidemiology and risk factors for (tardive) dyskinesia. Int Rev Neurobiol 2011, 98, 211-30.
74. Sagar, S. M.; Sharp, F. R.; Curran, T., Expression of c-fos protein in brain: metabolic mapping at the cellular level. Science 1988, 240 (4857), 1328-31.
75. Cochran, S. M.; McKerchar, C. E.; Morris, B. J.; Pratt, J. A., Induction of differential patterns of local cerebral glucose metabolism and immediateearly genes by acute clozapine and haloperidol. Neuropharmacology 2002, 43 (3), 394-407. (Pubitemid 35257931)
76. Sharp, F. R.; Sagar, S. M.; Swanson, R. A., Metabolic mapping with cellular resolution: c-fos vs. 2-deoxyglucose. Crit Rev Neurobiol 1993, 7 (3-4), 205-28. (Pubitemid 24181330)
77. Schwartz, W. J.; Smith, C. B.; Davidsen, L.; Savaki, H.; Sokoloff, L.; Mata, M.; Fink, D. J.; Gainer, H., Metabolic mapping of functional activity in the hypothalamo-neurohypophysial system of the rat. Science 1979, 205 (4407), 723-5. (Pubitemid 9253867)
78. Mata, M.; Fink, D. J.; Gainer, H.; Smith, C. B.; Davidsen, L.; Savaki, H.; Schwartz, W. J.; Sokoloff, L., Activity-dependent energy metabolism in rat posterior pituitary primarily reflects sodium pump activity. J Neurochem 1980, 34 (1), 213-5. (Pubitemid 10172700)
79. Auker, C. R.; Meszler, R. M.; Carpenter, D. O., Apparent discrepancy between single-unit activity and [14C]deoxyglucose labeling in optic tectum of the rattlesnake. J Neurophysiol 1983, 49 (6), 1504-16. (Pubitemid 13068859)
80. Mitchell, I. J.; Crossman, A. R.; Liminga, U.; Andren, P.; Gunne, L. M., Regional changes in 2-deoxyglucose uptake associated with neurolepticinduced tardive dyskinesia in the Cebus monkey. Mov Disord 1992, 7 (1), 32-7.
81. McCulloch, J.; Savaki, H. E.; Sokoloff, L., Distribution of effects of haloperidol on energy metabolism in the rat brain. Brain Res 1982, 243 (1), 81-90. (Pubitemid 12082366)
82. Pizzolato, G.; Soncrant, T. T.; Holloway, H. W.; Rapoport, S. I., Reduced metabolic response of the aged rat brain to haloperidol. J Neurosci 1985, 5 (11), 2831-8. (Pubitemid 16225481)
83. Pizzolato, G.; Soncrant, T. T.; Larson, D. M.; Rapoport, S. I., Reduced metabolic response of the rat brain to haloperidol after chronic treatment. Brain Res 1985, 337 (1), 1-9. (Pubitemid 15008279)
84. Colangelo, V.; Di Grezia, R.; Passarelli, F.; Musicco, M.; Pontieri, F. E.; Orzi, F., Differential effects of acute administration of clozapine or haloperidol on local cerebral glucose utilization in the rat. Brain Res 1997, 768 (1-2), 273-8. (Pubitemid 27433501)
85. Wotanis, J.; Hanak, S. E.; Wettstein, J. G.; Black, M. D., Comparative analysis of acute and chronic administration of haloperidol and clozapine using [3H] 2-deoxyglucose metabolic mapping. Schizophr Res 2003, 61 (2-3), 195-205. (Pubitemid 36519176)
86. Merchant, K. M.; Dorsa, D. M., Differential induction of neurotensin and cfos gene expression by typical versus atypical antipsychotics. Proc Natl Acad Sci U S A 1993, 90 (8), 3447-51. (Pubitemid 23111383)
87. Robertson, G. S.; Matsumura, H.; Fibiger, H. C., Induction patterns of Foslike immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J Pharmacol Exp Ther 1994, 271 (2), 1058-66. (Pubitemid 24377799)
88. Chartoff, E. H.; Ward, R. P.; Dorsa, D. M., Role of adenosine and N-methyl-D-Aspartate receptors in mediating haloperidol-induced gene expression and catalepsy. J Pharmacol Exp Ther 1999, 291 (2), 531-7. (Pubitemid 29503521)
89. Palacios, J. M.; Wiederhold, K. H., Dopamine D2 receptor agents, but not dopamine D1, modify brain glucose metabolism. Brain Res 1985, 327 (1-2), 390-4. (Pubitemid 15167338)
90. Palombo, E.; Porrino, L. J.; Bankiewicz, K. S.; Crane, A. M.; Sokoloff, L.; Kopin, I. J., Local cerebral glucose utilization in monkeys with hemiparkinsonism induced by intracarotid infusion of the neurotoxin MPTP. J Neurosci 1990, 10 (3), 860-9. (Pubitemid 20104784)
91. Morelli, M.; Pontieri, F. E.; Linfante, I.; Orzi, F.; Di Chiara, G., Local cerebral glucose utilization after D1 receptor stimulation in 6-OHDA lesioned rats: effect of sensitization (priming) with a dopaminergic agonist. Synapse 1993, 13 (3), 264-9. (Pubitemid 23098078)
92. Pizzolato, G.; Soncrant, T. T.; Rapoport, S. I., Haloperidol and cerebral metabolism in the conscious rat: relation to pharmacokinetics. J Neurochem 1984, 43 (3), 724-32. (Pubitemid 14065455)
93. Smith, Y.; Bevan, M. D.; Shink, E.; Bolam, J. P., Microcircuitry of the direct and indirect pathways of the basal ganglia. Neuroscience 1998, 86 (2), 353-87. (Pubitemid 28293917)
94. Greenamyre, J. T., The role of glutamate in neurotransmission and in neurologic disease. Arch Neurol 1986, 43 (10), 1058-63. (Pubitemid 16023670)
95. Choi, D. W.; Maulucci-Gedde, M.; Kriegstein, A. R., Glutamate neurotoxicity in cortical cell culture. J Neurosci 1987, 7 (2), 357-68. (Pubitemid 17017465)
96. Rogue, P.; Vincendon, G., Dopamine D2 receptor antagonists induce immediate early genes in the rat striatum. Brain Res Bull 1992, 29 (3-4), 469-72.
97. Robbins, M. J.; Critchlow, H. M.; Lloyd, A.; Cilia, J.; Clarke, J. D.; Bond, B.; Jones, D. N.; Maycox, P. R., Differential expression of IEG mRNA in rat brain following acute treatment with clozapine or haloperidol: a semiquantitative RT-PCR study. J Psychopharmacol 2008, 22 (5), 536-42.
98. Creed, M. C.; Hamani, C.; Nobrega, J. N., Early gene mapping after deep brain stimulation in a rat model of tardive dyskinesia: comparison with transient local inactivation. Eur Neuropsychopharmacol 2012, 22 (7), 506-17.
99. Hussain, N.; Flumerfelt, B. A.; Rajakumar, N., Glutamatergic regulation of haloperidol-induced c-fos expression in the rat striatum and nucleus accumbens. Neuroscience 2001, 102 (2), 391-9. (Pubitemid 32126493)
100. Rodriguez, J. J.; Garcia, D. R.; Nakabeppu, Y.; Pickel, V. M., FosB in rat striatum: normal regional distribution and enhanced expression after 6-month haloperidol administration. Synapse 2001, 39 (2), 122-32. (Pubitemid 32104017)
101. Robinet, E. A.; Geurts, M.; Maloteaux, J. M.; Pauwels, P. J., Chronic treatment with certain antipsychotic drugs preserves upregulation of regulator of G-protein signalling 2 mRNA in rat striatum as opposed to c-fos mRNA. Neurosci Lett 2001, 307 (1), 45-8. (Pubitemid 32539305)
102. Lee, J.; Rajakumar, N., Role of NR2B-containing N-methyl-D-Aspartate receptors in haloperidol-induced c-Fos expression in the striatum and nucleus accumbens. Neuroscience 2003, 122 (3), 739-45. (Pubitemid 37410295)
103. Doucet, J. P.; Nakabeppu, Y.; Bedard, P. J.; Hope, B. T.; Nestler, E. J.; Jasmin, B. J.; Chen, J. S.; Iadarola, M. J.; St-Jean, M.; Wigle, N.; Blanchet, P.; Grondin, R.; Robertson, G. S., Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of deltaFosB-like protein(s) in both the rodent and primate striatum. Eur J Neurosci 1996, 8 (2), 365-81. (Pubitemid 26041334)
104. Robertson, G. S.; Lee, C. J.; Sridhar, K.; Nakabeppu, Y.; Cheng, M.; Wang, Y. M.; Caron, M. G., Clozapine-, but not haloperidol-, induced increases in deltaFosB-like immunoreactivity are completely blocked in the striatum of mice lacking D3 dopamine receptors. Eur J Neurosci 2004, 20 (11), 3189-94. (Pubitemid 40007314)
105. Robertson, G. S.; Fibiger, H. C., Neuroleptics increase c-fos expression in the forebrain: contrasting effects of haloperidol and clozapine. Neuroscience 1992, 46 (2), 315-28.
106. Miwa, H.; Fuwa, T.; Nishi, K.; Mizuno, Y., Effects of the globus pallidus lesion on the induction of c-Fos by dopaminergic drugs in the striatum possibly via pallidostriatal feedback loops. Neurosci Lett 1998, 240 (3), 167-70. (Pubitemid 28079048)
107. Bertran-Gonzalez, J.; Bosch, C.; Maroteaux, M.; Matamales, M.; Herve, D.; Valjent, E.; Girault, J. A., Opposing patterns of signaling activation in dopamine D1 and D2 receptor-expressing striatal neurons in response to cocaine and haloperidol. J Neurosci 2008, 28 (22), 5671-85.
108. Tang, F.; Costa, E.; Schwartz, J. P., Increase of proenkephalin mRNA and enkephalin content of rat striatum after daily injection of haloperidol for 2 to 3 weeks. Proc Natl Acad Sci U S A 1983, 80 (12), 3841-4. (Pubitemid 13063150)
109. Merchant, K. M.; Dobner, P. R.; Dorsa, D. M., Differential effects of haloperidol and clozapine on neurotensin gene transcription in rat neostriatum. J Neurosci 1992, 12 (2), 652-63.
110. Konradi, C.; Kobierski, L. A.; Nguyen, T. V.; Heckers, S.; Hyman, S. E., The cAMP-response-element-binding protein interacts, but Fos protein does not interact, with the proenkephalin enhancer in rat striatum. Proc Natl Acad Sci U S A 1993, 90 (15), 7005-9. (Pubitemid 23222377)
111. Gunne, L. M.; Haggstrom, J. E., Reduction of nigral glutamic acid decarboxylase in rats with neuroleptic-induced oral dyskinesia. Psychopharmacology (Berl) 1983, 81 (3), 191-4. (Pubitemid 14249643)
112. Gunne, L. M.; Haggstrom, J. E.; Sjoquist, B., Association with persistent neuroleptic-induced dyskinesia of regional changes in brain GABA synthesis. Nature 1984, 309 (5966), 347-9. (Pubitemid 14145835)
113. Kapur, S.; Remington, G., Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Annu Rev Med 2001, 52, 503-17. (Pubitemid 32195338)
114. Stock, G.; Kummer, P., Long-term application of haloperidol: effects on dopamine and acetylcholine receptors. Int Pharmacopsychiatry 1981, 16 (3), 144-53. (Pubitemid 12235820)
115. Sanci, V.; Houle, S.; DaSilva, J. N., No change in dopamine D1 receptor in vivo binding in rats after sub-chronic haloperidol treatment. Can J Physiol Pharmacol 2002, 80 (1), 36-41. (Pubitemid 34194284)
116. Sasaki, T.; Kennedy, J. L.; Nobrega, J. N., Regional brain changes in [3H]SCH 23390 binding to dopamine D1, receptors after long-term haloperidol treatment: lack of correspondence with the development of vacuous chewing movements. Behav Brain Res 1998, 90 (2), 125-32. (Pubitemid 28080554)
117. Chiodo, L. A.; Bunney, B. S., Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J Neurosci 1983, 3 (8), 1607-19. (Pubitemid 13045297)
118. Kapur, S.; Barsoum, S. C.; Seeman, P., Dopamine D(2) receptor blockade by haloperidol. (3)H-raclopride reveals much higher occupancy than EEDQ. Neuropsychopharmacology 2000, 23 (5), 595-8.
119. Wadenberg, M. L.; Kapur, S.; Soliman, A.; Jones, C.; Vaccarino, F., Dopamine D2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats. Psychopharmacology (Berl) 2000, 150 (4), 422-9. (Pubitemid 30470221)
120. Crocker, A. D.; Hemsley, K. M., An animal model of extrapyramidal side effects induced by antipsychotic drugs: relationship with D2 dopamine receptor occupancy. Prog Neuropsychopharmacol Biol Psychiatry 2001, 25 (3), 573-90. (Pubitemid 32391539)
121. Turrone, P.; Remington, G.; Kapur, S.; Nobrega, J. N., The relationship between dopamine D2 receptor occupancy and the vacuous chewing movement syndrome in rats. Psychopharmacology (Berl) 2003, 165 (2), 166-71. (Pubitemid 36056993)
122. Pazos, A.; Probst, A.; Palacios, J. M., Serotonin receptors in the human brain-IV. Autoradiographic mapping of serotonin-2 receptors. Neuroscience 1987, 21 (1), 123-39. (Pubitemid 17076867)
123. Di Matteo, V.; Pierucci, M.; Esposito, E.; Crescimanno, G.; Benigno, A.; Di Giovanni, G., Serotonin modulation of the basal ganglia circuitry: therapeutic implication for Parkinson's disease and other motor disorders. Prog Brain Res 2008, 172, 423-63.
124. Di Giovanni, G.; Esposito, E.; Di Matteo, V., Role of serotonin in central dopamine dysfunction. CNS Neurosci Ther 2010, 16 (3), 179-94.
125. Numan, S.; Lundgren, K. H.; Wright, D. E.; Herman, J. P.; Seroogy, K. B., Increased expression of 5HT2 receptor mRNA in rat striatum following 6-OHDA lesions of the adult nigrostriatal pathway. Brain Res Mol Brain Res 1995, 29 (2), 391-6.
126. Creed-Carson, M.; Oraha, A.; Nobrega, J. N., Effects of 5-HT(2A) and 5-HT(2C) receptor antagonists on acute and chronic dyskinetic effects induced by haloperidol in rats. Behav Brain Res 2011, 219 (2), 273-9.
127. Wolf, W. A.; Bieganski, G. J.; Guillen, V.; Mignon, L., Enhanced 5-HT2C receptor signaling is associated with haloperidol-induced "early onset" vacuous chewing in rats: implications for antipsychotic drug therapy. Psychopharmacology (Berl) 2005, 182 (1), 84-94. (Pubitemid 41400865)
128. Ward, R. P.; Dorsa, D. M., Colocalization of serotonin receptor subtypes 5-HT2A, 5-HT2C, and 5-HT6 with neuropeptides in rat striatum. J Comp Neurol 1996, 370 (3), 405-14. (Pubitemid 26235237)
129. Eberle-Wang, K.; Lucki, I.; Chesselet, M. F., A role for the subthalamic nucleus in 5-HT2C-induced oral dyskinesia. Neuroscience 1996, 72 (1), 117-28.
130. Wichmann, T.; DeLong, M. R., Functional neuroanatomy of the basal ganglia in Parkinson's disease. Adv Neurol 2003, 91, 9-18.
131. Naidu, P. S.; Kulkarni, S. K., Reversal of neuroleptic-induced orofacial dyskinesia by 5-HT3 receptor antagonists. Eur J Pharmacol 2001, 420 (2-3), 113-7. (Pubitemid 32537685)
132. Gerlach, J.; Lublin, H.; Peacock, L., Extrapyramidal symptoms during longterm treatment with antipsychotics: special focus on clozapine and D1 and D2 dopamine antagonists. Neuropsychopharmacology 1996, 14 (3 Suppl), 35S-39S. (Pubitemid 26097612)
133. Miller, C. H.; Mohr, F.; Umbricht, D.; Woerner, M.; Fleischhacker, W. W.; Lieberman, J. A., The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics. J Clin Psychiatry 1998, 59 (2), 69-75. (Pubitemid 28141238)
134. Wirtshafter, D., Clozapine antagonizes the induction of striatal Fos expression by typical neuroleptics. Eur J Pharmacol 1998, 358 (3), R1-3. (Pubitemid 28498190)
135. Young, C. D.; Bubser, M.; Meltzer, H. Y.; Deutch, A. Y., Clozapine pretreatment modifies haloperidol-elicited forebrain Fos induction: a regionally-specific double dissociation. Psychopharmacology (Berl) 1999, 144 (3), 255-63. (Pubitemid 29307277)
136. Szczepanik, A. M.; Wilmot, C. A., Effects of ritanserin on haloperidolinduced dopamine (D2) receptor up-regulation in the rat. Neurosci Lett 1997, 231 (2), 91-4. (Pubitemid 27386497)
137. Osborne, P. G.; O'Connor, W. T.; Beck, O.; Ungerstedt, U., Acute versus chronic haloperidol: relationship between tolerance to catalepsy and striatal and accumbens dopamine, GABA and acetylcholine release. Brain Res 1994, 634 (1), 20-30. (Pubitemid 24013542)
138. Bolam, J. P.; Wainer, B. H.; Smith, A. D., Characterization of cholinergic neurons in the rat neostriatum. A combination of choline acetyltransferase immunocytochemistry, Golgi-impregnation and electron microscopy. Neuroscience 1984, 12 (3), 711-8. (Pubitemid 14092487)
139. Reid, M. S.; O'Connor, W. T.; Herrera-Marschitz, M.; Ungerstedt, U., The effects of intranigral GABA and dynorphin A injections on striatal dopamine and GABA release: evidence that dopamine provides inhibitory regulation of striatal GABA neurons via D2 receptors. Brain Res 1990, 519 (1-2), 255-60. (Pubitemid 20199696)
140. Ferre, S.; O'Connor, W. T.; Fuxe, K.; Ungerstedt, U., The striopallidal neuron: a main locus for adenosine-dopamine interactions in the brain. J Neurosci 1993, 13 (12), 5402-6. (Pubitemid 24001022)
141. Muller, P.; Seeman, P., Brain neurotransmitter receptors after long-term haloperidol: dopamine, acetylcholine, serotonin, alpha-noradrenergic and naloxone receptors. Life Sci 1977, 21 (12), 1751-8. (Pubitemid 8268314)
142. Terry, A. V., Jr.; Gearhart, D. A., Time dependent decreases in central alpha7 nicotinic acetylcholine receptors associated with haloperidol and risperidone treatment in rats. Eur J Pharmacol 2007, 571 (1), 29-32. (Pubitemid 47284053)
143. Klemm, W. R., Evidence for a cholinergic role in haloperidol-induced catalepsy. Psychopharmacology (Berl) 1985, 85 (2), 139-42. (Pubitemid 15108857)
144. Rupniak, N. M.; Jenner, P.; Marsden, C. D., Pharmacological characterisation of spontaneous or drug-Associated purposeless chewing movements in rats. Psychopharmacology (Berl) 1985, 85 (1), 71-9. (Pubitemid 15159600)
145. Algeri, S.; Achilli, G.; Cimino, M.; Perego, C.; Ponzio, F.; Vantini, G., Study on some compensatory responses of dopaminergic system in aging rats. Exp Brain Res 1982, Suppl 5, 146-52. (Pubitemid 12046587)
146. Ponzio, F.; Calderini, G.; Lomuscio, G.; Vantini, G.; Toffano, G.; Algeri, S., Changes in monoamines and their metabolite levels in some brain regions of aged rats. Neurobiol Aging 1982, 3 (1), 23-9. (Pubitemid 12066362)
147. Leelavathi, D. E.; Misra, C. H.; Shelat, H.; Smith, R. C., Effects of acute and chronic administration of phencyclidine on dopaminergic receptors in rat striatum. Commun Psychopharmacol 1980, 4 (5), 417-24. (Pubitemid 11039605)
148. Misra, C. H.; Shelat, H. S.; Smith, R. C., Effect of age on adrenergic and dopaminergic receptor binding in rat brain. Life Sci 1980, 27 (6), 521-6. (Pubitemid 11231295)